• Mashup Score: 0

    Charlotte Zuur, Leiden University Medical Center, Leiden, The Netherlands, discusses the clinical implications of the MATISSE trial (NCT02760498) for patients with cutaneous squamous cell carcinoma (CSCC). The trial results principally evaluated whether patients with a deep response to neoadjuvant immunotherapy might be spared intensive standard-of-care surgery and radiotherapy. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • Charlotte Zuur from @LUMC_Leiden sheds light on the MATISSE trial's impact, offering potential alternatives to intensive treatments for cutaneous squamous cell carcinoma: ➡️https://t.co/T0RD9RzpWu⬅️ #ASCO23 #CTSM #SkcSM

  • Mashup Score: 0

    Charlotte Zuur, Leiden University Medical Centre, Leiden, The Netherlands, outlines the primary objectives and results of the Phase II MATISSE study (NCT02760498) of nivolumab and nivolumab plus ipilimumab (two monoclonal antibodies targeting PD1 and CTLA-4 respectively) in extensive cutaneous squamous cell carcinoma (SCC). The randomised trial enrolled 40 patients with an indication for curative surgery with or without radiotherapy; the study aimed to improve patients’ clinical prospects through immunotherapy and de-escalate surgery and radiotherapy. Dr Zuur shared the promising results of the immunotherapy, stating 90% of patients who refused surgery displayed disease-free survival of 1 year. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved

    Tweet Tweets with this article
    • 🎥Dr Charlotte Zuur (@LUMC_Leiden) discusses promising results from the Phase II MATISSE study using nivolumab and nivolumab plus ipilimumab in extensive cutaneous squamous cell carcinoma: ➡️https://t.co/RI7WRXGEL8⬅️ #ASCO23 #ImmunoOnc #SkcSM #CTSM #TrialUpdate

  • Mashup Score: 0

    Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, talks on the trial design of the Phase III MAIN-CAV trial (NCT05092958) of maintenance cabozantinib and avelumab in patients with metastatic urothelial cancer. Based on the JAVELIN Bladder 100 trial (NCT02603432), maintenance avelumab is considered the standard of care in this setting, but responses remain poor in patients with certain metastases. The MAIN-CAV will assess the addition of cabozantinib in patients pre-treated with platinum-based chemotherapy, and overall survival will be the primary objective. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@shilpaonc (@ClevelndClinic) discusses the Phase III MAIN-CAV trial, aiming to improve outcomes for patients w/ metastatic UC via maintenance cabozantinib and avelumab: ➡️https://t.co/qMCOgJ49Dg⬅️ #ASCO23 #ImmunoOnc #CTSM #UroOnc #UroSoMe #BlcSM

  • Mashup Score: 1

    Ciara Conduit, FRACP, MBBS, PGCert MEd, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on updates from the CLIMATE trial (ACTRN12622000247774), which assessed the clinical utility of miR-371a-3p as a marker of residual disease in testicular cancer following orchiectomy. Having a post-operative biomarker will enable patients who test negative for minimal residual disease (MRD) to be spared treatment. Patients with seminoma and non-seminoma testicular cancer were recruited and the trial is currently ongoing. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@ciaraconduit from @PeterMacCC discusses promising updates from the CLIMATE trial, highlighting the potential of miR-371a-3p as a post-operative biomarker in testicular cancer: ➡️https://t.co/G8CbHIxyZk⬅️ #ANZUP23 #TSCSM #UroOnc #UroSoMe #CTSM

  • Mashup Score: 0

    Patrizia Giannatempo, MD, Foundation IRCCS National Cancer Institute, Milan, Italy, highlights the importance of understanding variant histologies in the context of treatment options for urothelial carcinoma, particularly immunotherapy and therapies like cabozantinib in neoadjuvant settings. Variant histologies in urothelial carcinoma often have limited alternatives compared to standard chemotherapy, and cystectomy is typically the first choice. However, emerging data from studies such as the Phase III KEYNOTE-045 (NCT02256436) and Phase II ARCADIA (NCT03824691) trials indicate that the treatment landscape for variant histologies could potentially change in the future. It is crucial to identify which subtypes of variants could benefit from pembrolizumab or the combination of durvalumab and cabozantinib. While the Arcadia trial is still ongoing and requires completion with 120 treated patients, the preliminary results are promising, indicating the need to further explore and understand

    Tweet Tweets with this article
    • 🎥@giannatempopatr emphasizes understanding variant histologies in UC treatment. Emerging data from trials like KEYNOTE-045 & ARCADIA could change the landscape for these variants: ➡️https://t.co/8Dm3BqClO2⬅️ #ASCO23 #BlcSM #CTSM #UroOnc #UroSoMe

  • Mashup Score: 0

    Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA, provides an overview of a Phase II (NCT03969706) trial evaluating the efficacy of abemaciclib, a selective CDK4/6 inhibitor, in patients with recurrent oligodendroglioma. The study included patients with IDH-mutant and 1p/19q-codeleted WHO Grade 3 oligodendroglioma who had previously received radiotherapy and alkylating chemotherapy. The primary endpoint was progression-free survival (PFS) status at 6 months. Ten patients were enrolled, and the most common treatment-related adverse event was grade 1-2 diarrhea. Among patients with enhancing tumors, partial response was observed in 2 patients, stable disease in 3 patients, progressive disease in 3 patients, and not evaluable in 1 patient. The median PFSl was 7.7 months. While some patients showed positive responses, the efficacy of abemaciclib in recurrent oligodendroglioma was not sufficient to justify further investigation as a monotherapy.

    Tweet Tweets with this article
    • 🎥Stephen Bagley, MD, of discusses Phase II trial evaluating abemaciclib in recurrent oligodendroglioma. While some positive responses were seen, further studies are needed for patient selection: ➡️https://t.co/Qaz1JjLbfn⬅️ #ASCO23 #BTSM #CTSM